Landmark-based stratification by at least 90% prostate-specific antigen decline and prostate-specific antigen nadir in androgen receptor pathway inhibitor–treated metastatic hormone-sensitive prostate cancer
Landmark-based stratification by at least 90% prostate-specific antigen decline and prostate-specific antigen nadir in androgen receptor pathway inhibitor–treated metastatic hormone-sensitive prostate cancer. // Prostate International. – URL: https://www.sciencedirect.com/science/article/pii/S2287888226000875?dgcid=rss_sd_all
Landmark-based stratification by at least 90% prostate-specific antigen decline and prostate-specific antigen nadir in androgen receptor pathway inhibitor–treated metastatic hormone-sensitive prostate cancer. Prostate International. https://www.sciencedirect.com/science/article/pii/S2287888226000875?dgcid=rss_sd_all
“Landmark-based stratification by at least 90% prostate-specific antigen decline and prostate-specific antigen nadir in androgen receptor pathway inhibitor–treated metastatic hormone-sensitive prostate cancer.” Prostate International.
@article{article63154,
title = {Landmark-based stratification by at least 90\% prostate-specific antigen decline and prostate-specific antigen nadir in androgen receptor pathway inhibitor–treated metastatic hormone-sensitive prostate cancer},
journal = {Prostate International},
url = {https://www.sciencedirect.com/science/article/pii/S2287888226000875?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...